Pulmonary Large Cell Neuroendocrine Carcinoma
文献类型：期刊论文
| 作者 | Yang, Lan1,2,3,4; Fan, Ying1,2,3,4; Lu, Hongyang1,2,3,4 |
| 刊名 | PATHOLOGY & ONCOLOGY RESEARCH
 |
| 出版日期 | 2022-10-11 |
| 卷号 | 28 |
| 关键词 | treatment diagnosis LCNEC imaging examination pathologic features prognosis |
| ISSN号 | 1219-4956 |
| DOI | 10.3389/pore.2022.1610730 |
| 通讯作者 | Lu, Hongyang(luhy@zjcc.org.cn) |
| 英文摘要 | Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare subtype of malignant pulmonary tumor. The incidence rate of LCNEC was reported to be 0.3%-3% in lung cancers. Although LCNEC is classified as non-small cell lung cancer (NSCLC), it is more aggressive and malignant than other NSCLC, and its biological behavior is similar to that of small cell lung cancer (SCLC). Most of the LCNEC patients are elderly smoking male and the clinical manifestations are not specific. The imaging manifestations of the tumors are often located in the periphery and the upper lobes, and the enlargement of mediastinal or hilar lymph nodes is common. The diagnosis is mainly based on pathology by the histological features and immunohistochemistry (IHC). Specific neuroendocrine markers such as chromogranin A (CgA), synaptophysin (Syn) and CD56 are usually diffusely positive in LCNEC, and found that insulinoma-associated protein (INSM1) and high rate of Ki-67 are helpful for diagnosis. More differential diagnoses also increase the difficulty of correctly diagnosing LCNEC. The rise of LCNEC molecular typing in recent years may be helpful for diagnosis and subsequent treatment. This review focuses on the epidemiological features, imaging studies, pathology, diagnosis, treatment, and prognosis of LCNEC. |
| WOS关键词 | HEALTH-ORGANIZATION CLASSIFICATION ; LUNG-CARCINOMA ; ADJUVANT CHEMOTHERAPY ; SURGICAL-MANAGEMENT ; PROTEIN-1 INSM1 ; TUMORS ; CANCER ; IRINOTECAN ; DIAGNOSIS ; EFFICACY |
| 资助项目 | Zhejiang Provincial Natural Science Foundation of China ; Huadong Medicine Joint Funds of the Zhejiang Provincial Natural Science Foundation of China ; Beijing Science and Technology Innovation Medical Development Foundation ; [LY20H290003] ; [LHDMY22H160003] ; [KC2021-JX-0186-58] |
| WOS研究方向 | Oncology ; Pathology |
| 语种 | 英语 |
| WOS记录号 | WOS:000874567500001 |
| 出版者 | FRONTIERS MEDIA SA |
| 资助机构 | Zhejiang Provincial Natural Science Foundation of China ; Huadong Medicine Joint Funds of the Zhejiang Provincial Natural Science Foundation of China ; Beijing Science and Technology Innovation Medical Development Foundation |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/129891]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Lu, Hongyang |
| 作者单位 | 1.Chinese Acad Sci, Inst Basic Med & Canc IBMC, Hangzhou, Peoples R China 2.Wenzhou Med Univ, Clin Med Coll 2, Wenzhou, Peoples R China 3.Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Zhejiang Key Lab Diag & Treatment Technol Thorac O, Hangzhou, Peoples R China 4.Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Dept Thorac Med Oncol, Hangzhou, Peoples R China |
| 推荐引用方式 GB/T 7714 | Yang, Lan,Fan, Ying,Lu, Hongyang. Pulmonary Large Cell Neuroendocrine Carcinoma[J]. PATHOLOGY & ONCOLOGY RESEARCH,2022,28. |
| APA | Yang, Lan,Fan, Ying,&Lu, Hongyang.(2022).Pulmonary Large Cell Neuroendocrine Carcinoma.PATHOLOGY & ONCOLOGY RESEARCH,28. |
| MLA | Yang, Lan,et al."Pulmonary Large Cell Neuroendocrine Carcinoma".PATHOLOGY & ONCOLOGY RESEARCH 28(2022). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。